Compare Microchip Technology Inc. (MCHP) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Microchip Technology Inc. vs Regeneron Pharmaceuticals Inc — how do they compare? Microchip Technology Inc. trades at $76.84 (market cap $42.37B), while Regeneron Pharmaceuticals Inc trades at $737.72 (market cap $76.40B). The key difference: Regeneron Pharmaceuticals Inc is the larger of the two by market cap, and Microchip Technology Inc. pays the higher dividend (2.33%). Which is the better fit depends on your goals — on Pluang, investors hold Microchip Technology Inc. for 62 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| MCHP | REGN | |
|---|---|---|
Market Cap | $42.37B | $76.40B |
Volume | 8,887,625 | 626,381 |
Sector | Technology | Health |
52-Week High | $102.97 | $852.03 |
52-Week Low | $49.02 | $557.73 |
Typical Hold Time | 62 Days | 107 Days |
Enterprise Value | $47.49B | $71.12B |
Dividend Yield | 2.33% | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MCHP trades at $75.52, down 7.06% over 24 hours amid a bearish technical signal. The company reported a net loss of -$500K for 2025, though it has beaten EPS estimates for the last three quarters. Analyst consensus is strongly bullish with a $110.50 price target, and recent news highlights expansion in Ethernet and 48V power portfolios, plus the completed acquisition of Hailo to bolster edge AI capabilities.
The outlook is mixed: strong analyst support and strategic acquisitions in growth areas like AI and data centers present upside, but high valuation ratios, significant debt, and recent profitability challenges pose risks. The stock's near-term performance will hinge on Q3 2026 earnings and execution in high-demand semiconductor segments.
Regeneron Pharmaceuticals (REGN) trades at $739.57, up 0.12% on the day, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company maintains robust profitability with a net income margin of 27.86%. A major $8 billion expansion of the immunology alliance with Sanofi, announced October 1, 2026, provides significant future revenue potential and strategic momentum.
The outlook is positive, supported by strong earnings, a lucrative partnership, and a consensus analyst price target of $846. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. The stock presents a compelling opportunity for growth investors, though volatility may persist near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Microchip Technology Inc.
Microchip became an independent company in 1989 when it was spun off from General Instrument. More than half of revenue comes from MCUs, which are used in a wide array of electronic devices from remote controls to garage door openers to power windows in autos. The company's strength lies in lower-end 8-bit MCUs that are suitable for a wider range of less technologically advanced devices, but the firm has expanded its presence in higher-end MCUs and analog chips as well.
Read more on MCHP →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
